Скачать книгу

Premier stent. Image provided courtesy of Boston Scientif...Figure 31.4 Chemical structure of PMBA and PVDF‐HFP. (a) Chemical structure ...

      29 Chapter 32Figure 32.1 Longitudinal Stent Deformation Angiography. (a) proximal LSD of ...Figure 32.2 SYNERGY stent design. SYNERGY incorporates multiple key design e...Figure 32.3 Evermine 50 EES thinnest (50 µm) strut platform.

      30 Chapter 33Figure 33.1 Continuous sinusoid technology. The sinusoid‐formed wire is heli...Figure 33.2 Key features of Resolute Onyx stent. Zotarolimus is released fro...Figure 33.3 Zotarolimus release kinetics of ZES. The Endeavor Resolute, Reso...

      31 Chapter 34Figure 34.1 Chemical structure of Biolimus. The replacement of hydrogen by a...Figure 34.2 Mechanism of action of Biolimus. The cytostatic effect (arrest o...Figure 34.3 The main components of the Biosensor International Biolimus‐elut...

      32 Chapter 35Figure 35.1 Metabolism of poly‐L‐lactic acid (PLLA). Hydrolysis of PLLA resu...Figure 35.2 Resorption rates of metal scaffolds. Drug release occurs within ...Figure 35.3 Angiography and OCT imaging at baseline and follow‐up with the s...Figure 35.4 PK Papyrus, covered single stent design.

      33 Chapter 36Figure 36.1 Abluminus DES+ system: an overview of the CoCr alloys L605, ablu...Figure 36.2 An overview of The DynamXTM Bioadaptor particularities, composed...

      34 Chapter 37Figure 37.1 Late phase of a normal coronary arteriogram in two plans. Note t...Figure 37.2 The hypothesis of “embryonic recall.” Note the analogy of pressu...Figure 37.3 Timetable of a typical PICSO study in a patient. Note that the t...Figure 37.4 PICSO catheter in place in a patient undergoing PCI and PICSO (s...

      35 Chapter 38Figure 38.1 Platelet adhesion, activation, and aggregation. The interaction ...Figure 38.2 The platelet activation pathways and the coagulation cascade. Ma...Figure 38.3 Established and new anticoagulants classified according to the t...

      36 Chapter 40Figure 40.1 Schematic depiction of the anti‐IIa and anti‐Xa activities of un...

      37 Chapter 43Figure 43.1 Proposed strategies for tailoring antithrombotic therapy accordi...

      38 Chapter 44Figure 44.1 Secondary Prevention in Patients with Clinical ASCVD [9].Figure 44.2 Definition of Major ASCVD Events Very High‐Risk of Future ASCVD ...Figure 44.3 Impact of Selected Healthcare and Lifestyle Interventions on Mor...

      39 Chapter 45Figure 45.1 Central role of ADP‐P2Y12 interaction in platelet aggregation an...

      40 Chapter 46Figure 46.1 During PCI, at the site of vascular injury, exposure of the sube...Figure 46.2 Measurement and mechanism of action of P2Y12 inhibitors.

      41 Chapter 47Figure 47.1 Swan‐Ganz catheter with inflated balloon at the distal tip.Figure 47.3 Normal hemodynamics.Figure 47.2 Swan‐Ganz catheter in (a) RA. (b) RV, (c) PA, and (d) PCPW posit...

      42 Chapter 48Figure 48.1 Surgical embolectomy. The patient presented with massive pulmona...Figure 48.2 (a) Rotatable pigtail catheter. (b) EkoSonic Endovascular System...Figure 48.3 Catheter‐based therapy for a patient with submassive PE. (a) Sad...Figure 48.4 The AngioVac System. Unwanted intravascular material is aspirate...

      43 Chapter 49Figure 49.1 The distribution and density of renal nerves in the proximal (a)...Figure 49.2 Magnetic resonance angiography of the renal arteries. Polar arte...

      44 Chapter 50Figure 50.1 30‐day events following TAVR according to surgical risk.Figure 50.2 Risk of thrombotic and bleeding events according to time after t...Figure 50.3 Possible antithrombotic management strategies following TAVR.

      45 Chapter 51Figure 51.1 Hemodynamic monitoring with a resting peak‐to‐peak gradient (lef...Figure 51.2 Angiography of the left coronary artery (a). Right anterior obli...Figure 51.3 Pre‐shaping the 0.014‐inch guidewire with two angles through a b...Figure 51.4 (a) Apical four‐chamber echocardiogram showing the hypertrophied...

      46 Chapter 52Figure 52.1 (a) Watchman device. (b) Amplatzer Cardiac Plug. (c) Amulet devi...Figure 52.2 (a) LAA measurements in the standard transesophageal echocardiog...Figure 52.3 (a) LAA angiography. The access sheath shows the markers corresp...Figure 52.4 Watchman access and delivery sheaths.

      47 Chapter 53Figure 53.1 The RoPE (Risk of Paradoxical Embolism) score is used to calcula...Figure 53.2 Atrial septum defect (ASD) rims. Atrial septum as viewed from th...Figure 53.3 Comparison of devices available for atrial septal defect (ASD) a...Figure 53.4 Intracardiac echocardiogram and corresponding fluoroscopic image...Figure 53.5 ASD closure with a Gore® Cardioform Septal Occluder. (a) TEE sho...Figure 53.6 ASD closure with a 37mm Gore® Cardioform ASD Occluder. (a) TEE s...

      48 Chapter 54Figure 54.1 Transcatheter aortic paravalvular leak closure. A: Top left: LV ...Figure 54.2 Transcatheter closure of paravalvular leak on a bioprosthetic mi...Figure 54.3 Transcatheter closure of traumatic VSD. Patient is a 23 year old...

      49 Chapter 55Figure 55.1 Valvuloplasty balloon sizes and corresponding crosssectional are...

      50 Chapter 56Figure 56.1 Transfemoral transcatheter aortic valve replacement using a ball...Figure 56.2 Transapical transcatheter aortic valve replacement using a ballo...

      51 Chapter 57Figure 57.1 (a) EnVeo PRO delivery system. (b) Evolut PRO+: composed of self...Figure 57.2 Boston Scientific ACURATE neo valve: self‐expanding nitinol devi...Figure 57.3 Portico valve with bovine pericardial tissue mounted on a self‐e...Figure 57.4 JenaValve prosthesis (JenaValve Technology, Inc, Irvine, CA, USA...Figure 57.5 Cerebral embolic protection devices under investigation for use ...

      52 Chapter 58Figure 58.1 Evaluation of coronary obstruction risk for valve‐in‐valve (VIV)...Figure 58.2 Transcatheter aortic valve replacement (TAVR) with Bioprosthetic...Figure 58.3 Evaluation of the risk for left ventricular outflow track obstru...Figure 58.4 Reverse LAMPOON technique. A transeptal puncture is performed, a...Figure 58.5 Retrograde LAMPOON technique in a patient undergoing transcathet...

      53 Chapter 59Figure 59.1 Management of transcatheter valve embolization complicated by ao...Figure 59.2 Performing coronary protection with the ‘chimney’ technique in a...

      54 Chapter 60Figure 60.1 Differential diagnosis for post‐TAVR hypotension.CVP, central ...

      55 Chapter 61Figure 61.1 Sapien 3 UltraTM THV System. (a) Sapien 3 UltraTM bioprosthesis,...Figure 61.2 Evolut PROTM THV system. (a) Evolut PROTM bioprosthesis with ext...Figure 61.3 Acurate neo TM THV and the expandable, iSleeve sheath.Figure 61.4 Large open‐cells, self‐expandable PorticoTM THV with bovine peri...Figure 61.5 AllegraTM THV, a self‐expandable nitinol frame, with bovine peri...

      56 Chapter 62Figure 62.1 Carpentier’s functional classification.Figure 62.2 Segmental valve analysis.Figure 62.3 (a) Barlow’s disease. (b) Fibroelastic deficiency.Figure 62.4 Principles of reconstructive surgery.Figure 62.5 Posterior leaflet quadrangular resection with annular plication....Figure 62.6 Ring selection based on sizing of the mitral valve: (i) measure ...Figure 62.7 Reoperation according to leaflet prolapse.

      57 Chapter 63Figure 63.1 Different shapes of dilator and sheaths used for transseptal cat...Figure 63.2 Different types of transseptal puncture needle.Figure 63.3 (a) The needle: proximal tip with an arrow and a tap; distal tip...Figure 63.4 Positioning of the needle. (a) The catheter and the needle are m...Figure 63.5 (a) Different TEE views with ideal site of puncture site for dif...Figure 63.6 Anatomical landmarks fused with fluoroscopic image in left anter...Figure 63.7 Fluoroscopic confimation in different views Transseptal puncture...Figure 63.8 Cardiac tamponade and common sites of injury.Figure 63.9 Presence of thrombus in left atrium (a) and right atrium (b) see...

      58 Chapter 64.1Figure 64.1.1 The MitraClip System. (a) The MitraClip System components: Ste...Figure 64.1.2 Mitraclip 4G. Available sizes.

      59 Chapter 64.2Figure 64.2.1 Preoperative MDCT in Prediction of LVOTO Risk. (a) Severe, hor...Figure 64.2.2 Imaging‐based guidance of TMVR with the Medtronic intrepid sys...

      60 Chapter 65Figure 65.1 (a) Transthoracic 2D; and (b) 3D echocardiogram showing thickene...Figure 65.2 Fluroscopic landmarks for septal puncture. (a) An imaginary hori...Figure 65.3 Salient steps of balloon mitral valvuloplasty (BMV). (a) Pigtail...Figure

Скачать книгу